A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder by Martin, J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/191895
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Archival Report
A Genetic Investigation of Sex Bias in the
Prevalence of Attention-Deﬁcit/Hyperactivity
Disorder
Joanna Martin, Raymond K. Walters, Ditte Demontis, Manuel Mattheisen, S. Hong Lee,
Elise Robinson, Isabell Brikell, Laura Ghirardi, Henrik Larsson, Paul Lichtenstein,
Nicholas Eriksson, 23andMe Research Team, Psychiatric Genomics Consortium: ADHD
Subgroup, iPSYCH–Broad ADHD Workgroup, Thomas Werge, Preben Bo Mortensen,
Marianne Giørtz Pedersen, Ole Mors, Merete Nordentoft, David M. Hougaard,
Jonas Bybjerg-Grauholm, Naomi R. Wray, Barbara Franke, Stephen V. Faraone,
Michael C. O’Donovan, Anita Thapar, Anders D. Børglum, and Benjamin M. Neale
ABSTRACT
BACKGROUND: Attention-deﬁcit/hyperactivity disorder (ADHD) shows substantial heritability and is two to seven
times more common in male individuals than in female individuals. We examined two putative genetic mechanisms
underlying this sex bias: sex-speciﬁc heterogeneity and higher burden of risk in female cases.
METHODS:We analyzed genome-wide autosomal common variants from the Psychiatric Genomics Consortium and
iPSYCH Project (n = 20,183 cases, n = 35,191 controls) and Swedish population register data (n = 77,905 cases, n =
1,874,637 population controls).
RESULTS: Genetic correlation analyses using two methods suggested near complete sharing of common variant
effects across sexes, with rg estimates close to 1. Analyses of population data, however, indicated that female in-
dividuals with ADHD may be at especially high risk for certain comorbid developmental conditions (i.e., autism
spectrum disorder and congenital malformations), potentially indicating some clinical and etiological heterogeneity.
Polygenic risk score analysis did not support a higher burden of ADHD common risk variants in female cases (odds
ratio [conﬁdence interval] = 1.02 [0.98–1.06], p = .28). In contrast, epidemiological sibling analyses revealed that the
siblings of female individuals with ADHD are at higher familial risk for ADHD than the siblings of affected male
individuals (odds ratio [conﬁdence interval] = 1.14 [1.11–1.18], p = 1.5E-15).
CONCLUSIONS: Overall, this study supports a greater familial burden of risk in female individuals with ADHD and
some clinical and etiological heterogeneity, based on epidemiological analyses. However, molecular genetic analyses
suggest that autosomal common variants largely do not explain the sex bias in ADHD prevalence.
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Attention-deﬁcit/hyperactivity disorder (ADHD) is a common
(w5% childhood prevalence), highly heritable (70%–80%)
neurodevelopmental disorder (1,2). Recent genome-wide
association studies (GWASs) implicate thousands of genetic
risk variants across the allele frequency spectrum (3–7).
The ﬁrst robust genome-wide signiﬁcant single nucleotide
polymorphisms (SNPs) were recently identiﬁed in a GWAS
meta-analysis of 20,183 ADHD cases and 35,191 controls/
pseudocontrols (7). While such efforts are beginning to shed
light on ADHD biology, secondary genome-wide analyses can
address important issues regarding the etiological and clinical
heterogeneity of ADHD.
In children, boys show a two to seven times higher ADHD
diagnosis rate than girls (1,8). The male excess is more
pronounced in individuals ascertained from clinics than from
the community, and this difference attenuates during adult-
hood (2). The reasons for the difference in childhood preva-
lence are unclear. Here, we present a series of analyses aimed
at elucidating the basis for this difference.
Sex-Speciﬁc Heterogeneity
One possibility is that female ADHD is qualitatively different
from male ADHD. Although the majority of twin studies have
not detected any quantitative or qualitative sex differences in
ADHD heritability (9–12), this does not necessarily imply that
the same genetic variants are involved in ADHD etiology in
both sexes. If ADHD in clinically diagnosed male individuals is
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distinct from ADHD in diagnosed female individuals, this could
yield differences in prevalence. Sex-based genetic heteroge-
neity in common variants has been shown for several complex
human traits (e.g., blood pressure, waist-hip ratio) (13,14).
Here, we assessed the genome-wide autosomal genetic cor-
relation of ADHD in male and female individuals to determine
whether genetic heterogeneity from common variation con-
tributes to the observed biased prevalence.
The absence of extensive sequencing data currently pre-
cludes analogous analyses of rare genetic variants. Instead, to
evaluate whether such variants play differential roles in male
and female individuals with ADHD, we used risk for comorbid
brain-related developmental disorders (i.e., autism spectrum
disorder [ASD], intellectual disability [ID], epilepsy, motor
developmental delay) and rare syndromic phenotypes (i.e.,
congenital malformations, syndromes related to chromosomal
abnormalities) as proxies for possible presence of de novo or
rare segregating alleles. Rare, highly deleterious (including
noninherited) genetic variation has been implicated in such
phenotypes (15–25). Indeed, comorbid ID has been associated
with an increased likelihood that an individual with ADHD is a
carrier of a large, rare copy number variant (CNV) (26). It has
also long been known that rare genetic syndromes (e.g., fragile
X syndrome, velocardiofacial syndrome) are associated with
ADHD (27,28). Evidence for an increase in comorbid conditions
in female individuals with ADHD, when compared with affected
male individuals, would imply a more severe syndromal
phenotypic presentation of ADHD in a higher proportion of
female individuals. Such more complex presentations are
arguably more likely to be linked to deleterious rare mutations.
A higher rate of these comorbidities in female individuals would
also be consistent with clinical heterogeneity, which may
pertain to the observed prevalence differences.
Female Protective Effect
Aside from heterogeneity, prevalence differences may be
caused by a female protective effect, whereby female in-
dividuals are resilient to developing ADHD and thus require a
higher burden of genetic liability to develop it. Three family
studies have observed indirect evidence for this hypothesis in
the form of increased risk of ADHD in ﬁrst-degree relatives of
affected female individuals compared with affected male in-
dividuals, suggesting that families with an affected female in-
dividual may have a higher burden of genetic risk (29–31). Not
all studies report an increase in the recurrence rate of ADHD in
relatives of female probands, however (32,33). Two molecular
genetic studies tested this hypothesis more directly using
ADHD GWAS discovery data to calculate the burden of com-
mon risk alleles, as estimated by polygenic risk scores (PRSs),
in independent samples. In both studies, female children with
ADHD-related phenotypes had higher scores for ADHD than
affected male individuals (3,34). Although these preliminary
studies are consistent with the family studies mentioned
above, they were based on small discovery studies. Additional
tests using large GWAS datasets are needed to test whether
there is an increased burden of common genetic risk variants
in female individuals with ADHD.
We present a series of analyses to test the qualitative and
quantitative difference hypotheses for the biased sex
prevalence in ADHD. First, autosomal common variant data
were used to estimate the genetic correlation of ADHD in male
and female individuals. We then used population register data
to examine whether female individuals with ADHD are at an
increased risk for comorbid developmental conditions
compared with affected male individuals. Next, genome-wide
autosomal SNP data were used to test whether female in-
dividuals diagnosed with ADHD carry a higher burden of
common risk variants than affected male individuals. Finally,
using register data, we tested whether relatives of female in-
dividuals with ADHD are at an increased risk for ADHD
compared with relatives of diagnosed male individuals.
METHODS AND MATERIALS
Genetic Data
Data for ADHD cases and controls were available from the
Psychiatric Genomics Consortium (PGC) and the Lundbeck
Foundation Initiative for Integrative Psychiatric Research
(iPSYCH). See GWAS publication for full details of quality
control, imputation, and principal components analysis (7) and
the Supplement for a more detailed description of all methods.
The iPSYCH samples were genotyped, processed, and
analyzed in 23 separate waves. See Supplemental Table S1 for
sex-stratiﬁed sample sizes for each PGC study and iPSYCH
wave. The total sample size after all quality control was n =
20,183 cases (25% female) and n = 35,191 pseudocontrols/
population controls (38% female). Analyses that were
restricted to European-only samples consisted of 19,099
cases and 34,194 controls. ADHD GWAS summary statistics
were also available from research participants of the personal
genetics company 23andMe Inc. (n = 5857 self-reported ADHD
cases, n = 70,393 controls) (Mountain View, CA).
GWAS Analyses
Sex-speciﬁc logistic regression GWAS analyses of imputed
autosomal data were performed in each PGC study and
iPSYCH wave separately. Results were ﬁltered for each study/
wave based on minor allele frequency, imputation quality, call
rate, and expected minor allele frequency in cases. Sex-
speciﬁc GWAS results for samples of European ancestry
were meta-analyzed and also ﬁltered based on sample size
and presence of each SNP in both sets of results. This yielded
results for n = 7,531,543 common variants (hereafter PGC 1
iPSYCH). GWAS summary statistics can be downloaded at
https://www.med.unc.edu/pgc/results-and-downloads.
Testing for Sex-Speciﬁc Heterogeneity
Bivariate linkage disequilibrium (LD) score regression (LDSC)
(35,36) analyses were run on the sex-speciﬁc meta-analyzed
summary statistics. The primary analyses (with greatest power)
are those for the full PGC 1 iPSYCH sample; we also exam-
ined estimates in the PGC and iPSYCH samples separately
using LDSC and a second method, genomic relatedness
matrix restricted maximum likelihood (GREML), using genome-
wide complex trait analysis (37). Because of strict restrictions
on access to individual genotypes, bivariate GREML analyses
(38) were performed separately in PGC and iPSYCH. Analyses
were restricted to European-only samples. Sex-speciﬁc
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heritability was estimated using univariate models (see
Supplement for detailed methods).
Testing the Female Protective Effect Hypothesis
A leave-one-study/wave-out approach was used to maximize
power and maintain independent target and discovery samples
for PRS analyses using the standard approach (39,40). GWAS
results from 23andMe were also included in discovery meta-
analyses. A PRS was calculated for each individual in each
target sample (European-only samples) by scoring the number
of alleles weighted by log(odds ratio [OR]) across the set of
clumped, meta-analyzed SNPs in PLINK version 1.9 (see
Supplemental Table S2). PRSs were standardized using
z-score transformations; ORs can be interpreted as increase in
risk of the outcome per standard deviation in PRS. Logistic
regression analyses including principal components were used
to test for association of PRS with sex in cases (female in-
dividuals were coded as 1). Results of these leave-one-study/
wave-out analyses were meta-analyzed.
Epidemiological Analyses
Analyses of Swedish register data were based on all in-
dividuals of known parents born in Sweden between 1987 and
2006, living in Sweden at least until 12 years of age (n = 77,905
ADHD cases and n = 1,874,637 population controls). See
Supplement for details of the sample and analyses.
Testing for Sex-Speciﬁc Heterogeneity
We assessed sex-speciﬁc differences in association between
ADHD and the following categories of developmental disor-
ders/syndromes: ID, ASD, developmental coordination disor-
der, epilepsy, congenital malformations, and chromosomal
abnormalities (see Supplemental Table S3 for details, including
International Classiﬁcation of Diseases codes). Generalized
estimating equations were used to test for the effect of an
ADHD-by-sex interaction term on each outcome, while
accounting for related samples.
Testing the Female Protective Effect Hypothesis
We estimated whether risk of ADHD in siblings of female in-
dividuals with ADHD was higher than that in siblings of
affected male individuals after adjusting for sex of the com-
parison sibling. Analyses stratiﬁed by sex of the comparison
sibling are also presented. Analyses were restricted to pairs of
full siblings where at least one child had an ADHD diagnosis
(n = 71,691 observations, including n = 21,784 unique index
individuals).
RESULTS
Sex-Speciﬁc Heterogeneity
Genetic Correlation. Figure 1 displays genetic correlation
(rg) results for male and female ADHD from bivariate analyses
using GREML and LDSC (see Supplemental Table S4 for exact
estimates). The LDSC rg estimate in the full dataset (PGC 1
iPSYCH) was near 1. Similar results were found for bivariate
GREML analyses in both iPSYCH and PGC and for the LDSC
analyses in the iPSYCH dataset. The LDSC estimate in the
PGC dataset was lower, but large standard errors were seen in
this dataset for both methods.
Additional cross-dataset and cross-sex LDSC genetic cor-
relation estimates were used to assess the extent of heteroge-
neity across PGC and iPSYCH (see Supplemental Figure S1 and
Table S5). The genetic correlation between these subsamples
wasnot signiﬁcantly different from1 [rg (SE) = 1.13 (0.22)]. Cross-
dataset rg values forPGCmale individualswith iPSYCHmaleand
female individuals were also not signiﬁcantly different from 1.
Estimates for PGC female individuals with iPSYCH female in-
dividuals were lower (signiﬁcantly different from 0 and 1),
although this is likely related to the small sample size of the PGC
female individuals (n = 1067 cases and n = 5178 controls).
SNP-h2 was estimated at 0.123 (SE = 0.025) in female in-
dividuals and 0.247 (SE = 0.021) in male individuals
(Supplemental Figure S2 and Table S4). Downsampling male
cases and controls randomly to match the female sample size
and case-control ratio showed more similar SNP-h2 estimates
(see Supplemental Figure S2 and Table S6). Results varying
the relative population prevalence assumed are shown in
Supplemental Table S7. Figure 2 summarizes these results,
illustrating the impact of the assumed male:female ratio (which
affects assumed sex-speciﬁc population prevalence rates) and
sample size on SNP-h2 estimates; SNP-h2 estimates increased
in male individuals and decreased in female individuals as the
ratio was increased, and downsampling male cases and con-
trols gave similar SNP-h2 estimates in both sexes.
Genome-Wide Association Studies. Sex-speciﬁc
quantile–quantile and Manhattan plots are shown in Figure 3.
Three loci were genome-wide signiﬁcant in the male-only
GWAS (n = 14,154 cases, n = 17,948 controls). No SNPs
surpassed the genome-wide signiﬁcance threshold in the
female-only GWAS (n = 4945 cases, n = 16,246 controls). (See
Supplemental Table S8 for top 10 LD-independent SNPs for
each GWAS, annotated with the nearest gene.)
Figure 1. Genetic correlation estimates for attention-deﬁcit/hyperactivity
disorder in male and female individuals obtained from genomic related-
ness matrix restricted maximum likelihood (GREML) and linkage disequi-
librium score regression (LDSC) for the Lundbeck Foundation Initiative for
Integrative Psychiatric Research (iPSYCH), Psychiatric Genomics Con-
sortium (PGC), and combined PGC 1 iPSYCH datasets. Because of strict
restrictions on raw individual genotype access and transfer, GREML ana-
lyses could only be performed separately in the PGC and iPSYCH samples.
Bars display standard errors. The horizontal dashed line indicates a genetic
correlation of 1. The estimator was left unconstrained for these analyses to
allow for an unbiased assessment of the standard errors of the estimates; as
such, some of the estimates exceed 1.
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Several secondary analyses support the high genetic cor-
relation, suggesting that there is little or no difference in the
ADHD results for male and female individuals. First, no
genome-wide signiﬁcant heterogeneity is observed when
meta-analyzing the sex-speciﬁc GWAS results (Supplemental
Figure S3). Second, a GWAS of sex-by-genotype interactions
for ADHD identiﬁes no variants with differential effects by sex,
nor does it show any deviation from the null distribution of test
statistics genome-wide (Supplemental Figure S4). Similarly,
GWAS results for ADHD in the combined sample with or
without including sex as a covariate are nearly perfectly
correlated, with a low standard error (rg = .97, SE = .007).
Narrowing the focus to only ADHD cases also ﬁnds no
genome-wide signiﬁcant differences between male and female
cases (Supplemental Figure S5). Although some genome-wide
inﬂation is observed for this ﬁnal analysis in the iPSYCH
sample, it is not replicated in the PGC data and appears to be
attributable to one locus driven by a single low-frequency
genotyped SNP (minor allele frequency = 0.02). Investigation
of this locus shows no support for differences between male
and female cases in neighboring genotyped SNPs, suggesting
that the signal is likely a technical artifact (Supplemental
Figure S6).
Epidemiological Analyses. We examined the association
between having an ADHD diagnosis and risk of having a
comorbid developmental phenotype using Swedish register
data. We were interested in whether there is an interaction
between sex and ADHD as it pertains to these
comorbidities. Supplemental Table S9 displays the frequency
of the disorder categories examined and the proportion of
individuals affected overall and split by ADHD case status
and sex. The male:female ratio for ADHD was 2:1. ADHD
cases were at higher risk for all diagnostic categories, as
compared with sex-matched controls (Table 1). Signiﬁcant
ADHD-by-sex interactions were observed for ASD and
congenital malformations, suggesting that although in the
context of ADHD both sexes are at increased risk for these
comorbid problems, the increase in risk is even higher in
female individuals compared with controls. A nominally sig-
niﬁcant association was observed for the interaction term for
ID, which did not survive correction for multiple testing
(Bonferroni correction for six independent tests: p-value
threshold = .0083). Secondary analyses of severity of ID
(where information was available) indicated that this weak
association signal came from mild ID (IQ = 50–70), not
moderate (IQ = 35–49) or severe/profound (IQ , 35) ID
(Supplemental Table S10). Interaction terms were nonsignif-
icant for epilepsy, developmental coordination disorder, and
chromosomal abnormalities.
Female Protective Effect Hypothesis
PRS Analysis. Results of meta-analyses of each leave-one-
study/wave-out regression analysis for ADHD PRS are
shown in Figure 4. There was no association of ADHD PRS
with sex in cases (OR [conﬁdence interval (CI)] = 1.02
[0.98–1.06], p = .28, mean R2 [SE] = .0019 [.00039]). Sensi-
tivity tests were run excluding the data from 23andMe and
non-European ancestry individuals and then also not
including sex as a covariate in the discovery GWAS analyses;
results remained similar (Supplemental Figure S7). There was
no association of ADHD PRS with sex in controls (OR [CI] =
0.99 [0.96–1.01], p = .23, mean R2 [SE] = .0011 [.00024])
(Supplemental Figure S8). Mothers and fathers (in parent-
offspring trio design studies) also did not differ in ADHD
PRS (Supplemental Table S11).
There was a clear association of ADHD PRS with ADHD
case status, with similar differences in PRS between cases and
controls observed for female individuals (OR [CI] = 1.57
[1.50–1.64], p = 4.1xE-91, mean R2 [SE] = .039 [.0034]) and
male individuals (OR [CI] = 1.50 [1.46–1.53], p = 7.3xE-216,
mean R2 [SE] = .032 [.0024]). In this analysis, several individual
PGC studies did not show a signiﬁcant association with case-
control status in female individuals; this is likely due to low
power (e.g., n = 27 female case/pseudocontrol pairs in the
Canadian study).
Epidemiological Analysis. To test for evidence of
increased risk for ADHD in siblings of female individuals with
ADHD, we used Swedish population data to select sibling
pairs where at least one child had ADHD. The results showed
that siblings of female individuals diagnosed with ADHD are
at higher risk for ADHD than siblings of affected male in-
dividuals (OR [CI] = 1.14 [1.11–1.18], p = 1.5E-15); results
stratiﬁed by comparison sibling sex were similar for male
individuals (OR [CI] = 1.18 [1.13–1.23], p = 1.8E-13) and
female individuals (OR [CI] = 1.09 [1.01–1.16], p = .017).
Covarying for presence of ASD, congenital malformations,
Figure 2. Sex-speciﬁc single nucleotide polymorphism (SNP) herita-
bility estimates for attention-deﬁcit/hyperactivity disorder, varying the
assumed population prevalence based on different male:female ratios
(ranging from 1:1 to 7:1). Estimates are presented for the total available
sample of male individuals as well as for a downsampled set of male
cases and controls to match the available sample size in female
individuals.
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and ID in the proband did not affect the overall results (OR
[CI] = 1.15 [1.11–1.19], p = 7.3E-16).
DISCUSSION
We tested two speciﬁc hypotheses for the male bias in ADHD:
ﬁrst, that sex-speciﬁc genetic heterogeneity may affect prev-
alence rates via clinical heterogeneity in ADHD diagnosis by
sex, and second, that female individuals affected with ADHD
may carry an increased burden of genetic risk variants
compared with affected male individuals. We analyzed auto-
somal common variant data from the largest available ADHD
case-control GWAS sample (n = 55,374 individuals) and
Swedish population register data (n = 1,952,542 individuals).
We demonstrated a high level of genome-wide autosomal
genetic correlation for ADHD across sex and found no in-
crease of polygenic burden in affected female individuals
compared with affected male individuals. However, in register-
based data, we observed that siblings of female individuals
with ADHD are at increased risk for ADHD compared with
siblings of affected male individuals. The results also sug-
gested that female individuals diagnosed with ADHD may be
at an especially high risk for certain comorbid developmental
conditions.
The observed high SNP-based genetic correlation (consis-
tent across two methods) suggests that largely the same
common autosomal risk variants are involved in ADHD for both
sexes. While sex-speciﬁc heterogeneity from common auto-
somal variants seems unlikely based on our results, we cannot
rule out the possibility that heterogeneous effects exist for rare
or nonautosomal variation or that with increased sample sizes,
weaker effects of common variant heterogeneity could be
detected.
Indeed, the epidemiological analyses of Swedish population
data suggest some degree of clinical and/or etiological het-
erogeneity. ADHD was associated with comorbid diagnoses of
developmental conditions in both sexes. The strength of as-
sociation was greater in female individuals for ASD, congenital
malformations, and (to a lesser extent) mild ID, but it was
similar for both sexes for motor problems, epilepsy, and
chromosomal abnormalities. There are several possible ex-
planations for these ﬁndings.
First, female individuals with ADHD may have a higher than
expected risk of comorbid severe conditions and so may have
a higher level of clinical heterogeneity as compared with male
cases. This could indirectly point to a greater role of rare
deleterious variants in female individuals with ADHD because
such variants are strongly implicated in some of the comorbid
Figure 3. Quantile–quantile and Manhattan plots for sex-speciﬁc genome-wide association meta-analyses. (A) Female case-control analysis quantile–
quantile plot. (B) Female case-control analysis Manhattan plot. (C)Male case-control analysis quantile–quantile plot. (D)Male case-control analysis Manhattan
plot. In (B) and (D), the horizontal red (upper) line indicates genome-wide signiﬁcance (p , 5E-8) and the horizontal green (lower) line indicates suggestive
subthreshold signals (p , 5E-6).
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conditions assessed (15–25) and this effect has been seen in
other neurodevelopmental disorders (15–19). However, this
needs to be tested directly because common variants also play
an important role in such complex disorders (41,42), and little is
currently known about the contribution of rare variants to
ADHD.
An alternative explanation for the results is that ascertain-
ment and diagnostic biases, where female individuals are more
likely to be diagnosed with ADHD if they have a more severe
phenotypic presentation, could be involved. Individuals who
receive one diagnosis become the focus of clinical attention
and are more likely to receive subsequent diagnoses, whereas
individuals with less complex phenotypes might not come to
clinical attention. If female individuals are routinely under-
diagnosed with ADHD or other neurodevelopmental disorders,
this issue may disproportionately affect ascertainment of
Table 1. Results of Logistic Regression Analyses of ADHD Case Status on Comorbid Developmental Conditions, Stratiﬁed by
Sex, in the Swedish Population Sample (Total N = 1,952,542)
Outcome Sex
% of ADHD Cases
With Outcome
Sex-Speciﬁc Association ADHD by Sex Interaction
OR LCI UCI p OR LCI UCI p
ASD Male 14.82 18.91 18.33 19.50 , 2.2E-308a 1.52 1.44 1.61 2.9E-50a
Female 12.04 28.68 27.38 30.04 , 2.2E-308a
DCD Male 1.86 17.90 16.38 19.57 , 2.2E-308a 0.97 0.82 1.14 .71
Female 1.08 17.61 15.25 20.33 , 2.2E-308a
ID Male 5.30 9.82 9.38 10.28 , 2.2E-308a 1.11 1.03 1.20 .0090
Female 4.89 10.89 10.23 11.60 , 2.2E-308a
Epilepsy Male 2.57 3.27 3.09 3.47 , 2.2E-308a 1.08 0.99 1.19 .099
Female 2.85 3.55 3.29 3.82 6.6E-238a
Congenital Malformations Male 8.20 1.40 1.36 1.45 1.8E-109a 1.11 1.05 1.17 2.5E-04a
Female 6.46 1.54 1.47 1.62 8.9E-72a
Chromosomal Abnormalities Male 0.60 2.96 2.63 3.34 2.7E-70a 0.84 0.68 1.03 .096
Female 0.52 2.48 2.07 2.96 9.5E-24a
Sex is coded as 0 for male and 1 for female. Birth year is included as a covariate.
ADHD, attention-deﬁcit/hyperactivity disorder; ASD, autism spectrum disorder; DCD, developmental coordination disorder; ID, intellectual
disability; LCI, lower conﬁdence interval; OR, odds ratio; UCI, upper conﬁdence interval.
aEstimated p value below a Bonferroni-adjusted threshold for multiple testing (p , .0083).
Figure 4. Forest plots of meta-analysis results for logistic regression analyses of attention-deﬁcit/hyperactivity disorder polygenic risk scores with case sex
as the outcome (A), case-control status in female individuals (B), and case-control status in male individuals (C). Box sizes reﬂect sample sizes. Refer to
Table 1 for exact sample sizes. CIs, conﬁdence intervals; iPSYCH, Lundbeck Foundation Initiative for Integrative Psychiatric Research; PGC, Psychiatric
Genomics Consortium.
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female cases, leading to the observed pattern of results. Other
possible sources of bias include typical exclusion criteria for
diagnosing ADHD (e.g., ID, ASD) and the possibility of an
inﬂated false positive rate of diagnoses due to diagnostic un-
certainty and change over time. We limited the impact of the
latter by considering diagnoses only in individuals with at least
two reported diagnoses. Although the results are consistent
with increased etiological heterogeneity in female individuals
with ADHD, studies of rare variation are required to rule out
these alternative explanations.
Epidemiological analyses also showed that siblings of fe-
male individuals diagnosed with ADHD were at higher risk for
being diagnosed with ADHD than siblings of diagnosed male
individuals. This conﬁrms results from previous family studies
(29–31) indirectly supporting the hypothesis that female in-
dividuals require a greater burden of genetic risk to manifest
ADHD. Although these analyses do not distinguish between
genetic and shared environmental effects, twin studies have
consistently demonstrated high heritability of ADHD with
typically nonsigniﬁcant contributions from shared environ-
mental factors (2), suggesting that this effect is most likely to
be genetic in origin. However, the effect sizes were not large
(OR = 1.09–1.18), suggesting that any increased burden of
inherited genetic variation might be only a small contribution to
the sex bias in ADHD prevalence. These results could also
occur if clinicians had a higher threshold for diagnosing ADHD
in female individuals or were more likely to diagnose it if
accompanied by a comorbid disorder. However, the results did
not attenuate when comorbid conditions were accounted for.
Alternatively, sex-speciﬁc ascertainment biases could inﬂate
estimated risk of ADHD in siblings of female individuals.
Although female cases were more likely to be ascertained if
they had an already diagnosed brother (64.6%) than vice
versa, the sex-stratiﬁed results indicate that such biases
cannot fully explain our results. A limitation of the analyses was
restricting the sample to full siblings, which may have led to a
conservative estimate of the effect size and the possibility that
the results might not generalize to families with one child or
half-siblings.
Contrary to smaller studies (3,34), we did not ﬁnd an
enrichment of polygenic burden from common variants in fe-
male individuals compared with male individuals with ADHD.
Consistently, analyses in ASD have not found an increased
burden from common variants in affected female individuals
(43,44), in contrast to rare variant studies (15–19).
One possibility is that a higher degree of genetic hetero-
geneity within female individuals masked any differences in
PRS burden by sex in the current study. Common and rare
variants may contribute additively to ADHD risk, with non-CNV
carrier cases having lower ADHD PRSs than cases with large
rare CNVs (45). Thus, if female cases are more likely to have a
complex syndromic phenotype (as suggested by the register-
based analyses), and given that such phenotypes are more
likely to be associated with rare variants (15–25), this subgroup
of female individuals could have on average lower PRSs than
male individuals with ADHD. On the other hand, affected fe-
male individuals with a less severe phenotypic presentation,
who are not carriers of such rare variants, could have higher
PRSs than affected male individuals. If this were the case, any
overall differences in PRS between the sexes could be
obscured. Although the variance in ADHD PRS did not appear
to differ between male and female cases (p = .31; see
Supplement), limited power of this analysis prevents us from
conclusively ruling out this possibility.
Although the focus of this paper is on possible genetic
sources of inﬂuence on ADHD sex bias, other factors, such as
ascertainment and diagnostic biases, may play an important
role. Female individuals are more likely to be diagnosed with
the predominantly inattentive subtype of ADHD, whereas male
individuals are more likely to be diagnosed with the combined
subtype of ADHD and present with hyperactive-impulsive and
disruptive behavioral problems (46–49). Relative prevalence
rates also vary by diagnostic instrument used and case
ascertainment. For example, the ratio of male:female cases in
the Swedish population was 2:1, somewhat lower than that in
the iPSYCH Danish population (2.8:1) and PGC clinical data
(3.5:1). Individuals with moderate to severe ID (IQ , 50) were
excluded from iPSYCH. ADHD cases in the PGC studies were
primarily ascertained from clinics; ADHD was conﬁrmed with
structured interviews, and children with comorbid ASD, epi-
lepsy, ID (IQ , 70), and other conditions were excluded. As
such, the false positive rate for an ADHD diagnosis is likely
higher in the iPSYCH and Swedish register-based datasets
than in the PGC studies, while the latter is likely underrepre-
sented for individuals with neurodevelopmental comorbidities.
Another major difference is that many of the PGC studies used
DSM criteria and thus included children with inattentive and
hyperactive-impulsive subtypes of ADHD, whereas the
Swedish and iPSYCH studies (and some European PGC
studies) used the stricter International Classiﬁcation of Dis-
eases deﬁnition. Despite these differences, we ﬁnd very high
genetic correlation between PGC and iPSYCH, suggesting that
overall these diagnostic differences have no perceptible
impact on the involvement of common risk variants. PGC-only
and iPSYCH-only sex-speciﬁc analysis results were similar,
with the caveat that the PGC study was smaller and results had
larger conﬁdence intervals.
Another possible contribution to sex bias, beyond the scope
of the current study, is the role of sex hormones and chro-
mosomes. There is evidence for a speciﬁc role of sex hor-
mones (e.g., estrogen) and sex chromosomes (e.g., X
chromosome aneuploidy) in early brain development and
neurodevelopmental disorders such as ADHD (28,50,51),
suggesting that future efforts to examine the role of sex
chromosomes and their downstream products in ADHD may
be worthwhile. Future studies should also examine the degree
of shared genetic risks across ADHD and other developmental
conditions (e.g., ASD, ID, congenital abnormalities) in a sex-
speciﬁc manner as well as the role of rare variants (e.g.,
CNVs, single nucleotide mutations) in ADHD sex bias.
The results of this study demonstrate a clear polygenic
contribution from common autosomal genetic variants to
ADHD in both sexes, as evidenced by moderate SNP-h2 esti-
mates using two methods (similar in both sexes once
nonrandom sample ascertainment is taken into account via
sample size matching), clear deviation of test statistics on sex-
speciﬁc GWAS quantile–quantile plots, and signiﬁcantly higher
overall PRSs in cases compared with sex-matched controls.
Top hits from sex-speciﬁc GWAS analyses corroborate results
from a combined analysis of both sexes (7).
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The high genetic correlation and lack of difference in poly-
genic burden between male and female ADHD cases support
combiningGWASdata fromboth sexes in ADHDmeta-analyses
and further suggest that current clinical practices of diagnosing
ADHD are capturing a clinical phenotype that is similar at the
level of common genetic risk variants in both sexes. Thus, our
results indicate that genome-wide autosomal common variants
largely do not explain the observed sex bias in ADHD preva-
lence. On the other hand, the epidemiological results also
suggest some degree of clinical heterogeneity, with ADHD
showing a stronger phenotypic association with comorbid ASD,
congenital malformations, and mild ID in female individuals. We
also found evidence for a modest increase in familial risk for
ADHD in female individuals based on sibling analysis. Further
work simultaneously examining variants across the spectrum of
frequencies is needed to comprehensively determine the role of
genetic risk in the sex bias in ADHD prevalence.
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